» Articles » PMID: 28903383

Association Between ABO Blood Types and Sporadic Pancreatic Neuroendocrine Tumors in the Chinese Han Population

Overview
Journal Oncotarget
Specialty Oncology
Date 2017 Sep 15
PMID 28903383
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although the relationship between non-O blood types and the risk of exocrine pancreatic cancer has been demonstrated, the association between ABO blood types and sporadic pancreatic neuroendocrine tumor (PNET) has not been reported thus far.

Methods: This hospital-based, case-control study included 387 patients with PNET and 542 age- and sex-matched controls. Unconditional multivariable logistic regression analysis was performed to estimate the adjusted odds ratios (AORs) and 95% confidence intervals (CIs). The relationship between ABO blood types and clinicopathologic features was also analyzed.

Results: After adjusting for age, sex, smoking status, alcohol drinking, and first-degree family history of any cancer, the AORs (95% CI) of functional PNET were 0.87 (0.59-1.28) for blood type A, 0.86 (0.58-1.28) for blood type B, and 0.71 (0.39-1.26) for blood type AB compared with subjects with blood type O. A similar ABO blood-type distribution was observed among cases with non-functional PNETs compared with controls. On comparing blood type B with non-B blood type, cases with non-functional PNETs had marginally higher rates of lymph node invasion (P = 0.047), distant metastasis (P = 0.044), and advanced European Neuroendocrine Tumor Society Stage (P = 0.040).

Conclusions: There is no association between the ABO blood group and the development of functional and non-functional PNETs. The ABO blood types are not associated with the clinicopathologic features in patients with functional and non-functional PNETs.

Citing Articles

ABO blood group polymorphism has an impact on prostate, kidney and bladder cancer in association with longevity.

Stakisaitis D, Jukneviciene M, Ulys A, Zaliuniene D, Stanislovaitiene D, Sepetiene R Oncol Lett. 2018; 16(1):1321-1331.

PMID: 30061952 PMC: 6063046. DOI: 10.3892/ol.2018.8749.

References
1.
Low S, Kuchiba A, Zembutsu H, Saito A, Takahashi A, Kubo M . Genome-wide association study of pancreatic cancer in Japanese population. PLoS One. 2010; 5(7):e11824. PMC: 2912284. DOI: 10.1371/journal.pone.0011824. View

2.
Weisbrod A, Liewehr D, Steinberg S, Patterson E, Libutti S, Linehan W . Association of type O blood with pancreatic neuroendocrine tumors in Von Hippel-Lindau syndrome. Ann Surg Oncol. 2012; 19(6):2054-9. PMC: 7472877. DOI: 10.1245/s10434-012-2276-8. View

3.
Yao J, Hassan M, Phan A, Dagohoy C, Leary C, Mares J . One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26(18):3063-72. DOI: 10.1200/JCO.2007.15.4377. View

4.
Ichikawa D, Handa K, Withers D, Hakomori S . Histo-blood group A/B versus H status of human carcinoma cells as correlated with haptotactic cell motility: approach with A and B gene transfection. Cancer Res. 1997; 57(15):3092-6. View

5.
Fukumoto K, Taniguchi T, Usami N, Kawaguchi K, Fukui T, Ishiguro F . The ABO blood group is an independent prognostic factor in patients with resected non-small cell lung cancer. J Epidemiol. 2014; 25(2):110-6. PMC: 4310871. DOI: 10.2188/jea.JE20140102. View